人源间充质干细胞微囊泡在离体灌注人肺重度大肠杆菌肺炎中的治疗作用
本研究在离体灌注人肺模型中,向供体肺支气管内滴入大肠杆菌,1小时后经灌注液给予人间充质干细胞微囊泡(MSC MVs)。6小时后,MSC MVs显著增加肺泡液体清除率并降低蛋白通透性,Poly(I:C)预处理MSC可增强MVs的抗菌活性。
要点
- MSC MVs可增加重度大肠杆菌肺炎离体人肺的肺泡液体清除率。
- MSC MVs可降低损伤肺的蛋白通透性。
- Poly(I:C)预处理MSC可增强MVs的抗菌活性。
核心结论
- MSC MVs增加肺泡液体清除率并降低肺蛋白通透性。
- Poly(I:C)预处理MSC可增强MVs在离体灌注人肺中的抗菌活性。
研究设计与样本
- 使用未用于移植的人供体肺建立离体灌注人肺细菌肺炎模型。
- 支气管内滴入大肠杆菌,1小时后经灌注液给予MSC MVs作为治疗。
主要发现
- 滴入大肠杆菌6小时后,炎症细胞流入导致显著炎症、肺蛋白通透性增加和肺水肿形成。
- 给予MSC MVs显著增加肺泡液体清除率并降低蛋白通透性。
- MSC MVs在数值上降低损伤肺泡内的细菌负荷。
- Poly(I:C)预处理MSC后分离的MVs对杀菌的有益效应更明显。
- 体外实验中,MSC MV处理增加分离的人肺泡巨噬细胞的抗菌活性。
关键数值与推荐
- 损伤组与治疗组之间氧合和肺顺应性水平相似。
- 给予MSC MVs在数值上降低6小时中位肺动脉压。
临床怎么用
- MSC MVs可能作为重度细菌性肺炎急性肺损伤的潜在治疗策略。
- Poly(I:C)预处理MSC可增强MVs抗菌活性,提示可优化MVs制备。
局限性
- 研究为离体灌注人肺模型,非在体临床研究。
- 部分结果(如细菌负荷、肺动脉压)仅为数值变化,未报告统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We previously reported that microvesicles (MVs) released by human mesenchymal stem cells (MSC) were as effective as the cells themselves in both Escherichia coli lipopolysaccharide and live bacteria-induced acute lung injury (ALI) mice models. However, it remained unclear whether the biological effect of MSC MV can be applied to human ALI. METHODS: In the current study, we tested the therapeutic effects of MSC MVs in a well-established ex vivo perfused human model of bacterial pneumonia. Using human donor lungs not used for transplantation, we instilled E. coli bacteria intrabronchially and, 1 hour later, administered MSC MVs into the perfusate as therapy. RESULTS: After 6 hours, instillation of E. coli bacteria caused influx of inflammatory cells, which resulted in significant inflammation, lung protein permeability and pulmonary oedema formation. Administration of MSC MV significantly increased alveolar fluid clearance and reduced protein permeability and numerically lowered the bacterial load in the injured alveolus. The beneficial effect on bacterial killing was more pronounced with pretreatment of MSCs with a Toll-like receptor 3 agonist, polyinosinic:polycytidylic acid (Poly (I:C)), prior to the isolation of MVs. Isolated human alveolar macrophages had increased antimicrobial activity with MSC MV treatment in vitro as well. Although oxygenation and lung compliance levels were similar between injury and treatment groups, administration of MSC MVs numerically decreased median pulmonary artery pressure at 6 hours. CONCLUSIONS: In summary, MSC MVs increased alveolar fluid clearance and reduced lung protein permeability, and pretreatment with Poly (I:C) enhanced the antimicrobial activity of MVs in an ex vivo perfused human lung with severe bacteria pneumonia.
引用
- Park J, Kim S, Lim H, et al. Therapeutic effects of human mesenchymal stem cell microvesicles in an ex vivo perfused human lung injured with severe E. coli pneumonia. Thorax. 2018. PMID: 30076187. doi:10.1136/thoraxjnl-2018-211576
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。